Company: MIRA
Filing Date: 2025-04-11
Form Type: 8-K
Source: 0001641172-25-003889
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-04-11
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01.      Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.  

On April 8, 2025, MIRA Pharmaceuticals,
Inc. (the “ Company”) received a letter from the Nasdaq Listing Qualifications Staff indicating that, based on the Company’s
stockholders’ equity of $2,199,750 as of December 31, 2024, the Company does not currently meet the minimum stockholders’
equity requirement of $2.5 million as set forth under Nasdaq Listing Rule 5550(b)(1). Importantly, this notice does not affect the Company’s
listing status or the trading of its common stock, which will continue uninterrupted on the Nasdaq Capital Market under the ticker symbol
“ MIRA.”

In accordance with Nasdaq procedures,
the Company has been provided 45 calendar days, or until May 23, 2025, to submit a plan to Nasdaq outlining the actions it intends to
take to regain compliance. Upon review, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the notice.

The Company is preparing a plan
to restore compliance and is confident in its ability to meet the listing requirements within the allowed timeframe. Among other initiatives,
the Company anticipates completing its previously announced acquisition of SKNY Pharmaceuticals, Inc., a transaction expected to include
a $5 million capital infusion - composed of cash or equivalent consideration - which will significantly enhance the Company’s
balance sheet. The Company is also actively engaged in discussions with strategic investors to further strengthen its capital position.
The Company remains highly focused on making sound capital-raising decisions that align with its long-term vision and protect shareholder
value.

Additionally, the Company is progressing
its Phase 1 clinical trial for Ketamir-2, its next-generation oral ketamine analog for neuropathic pain. The first subject has been successfully
dosed, and the trial is advancing smoothly. Early data also shows promise in the drug’s topical formulation, which may further broaden
its clinical utility.

The Company remains committed
to advancing its neuroscience pipeline and near-term regulatory milestones. The Company is also excited about the potential of SKNY-1
as a novel therapeutic candidate for obesity and smoking cessation - two areas of significant unmet medical need. These combined efforts
are expected to support continued listing and drive long-term shareholder value.

Cautionary Note Regarding
Forward Looking Statements